Pharma BD Deal Intelligence
A mixed-outcome bet on Sanofi's $3.7B all-cash acquisition of Principia Biopharma's BTK-inhibitor platform: rilzabrutinib delivered, winning FDA approval as WAYRILZ in August 2025 as the first BTK inhibitor for chronic immune thrombocytopenia. But tolebrutinib, the deal's headline multiple sclerosis asset, hit an FDA Complete Response Letter in December 2025.
Sanofi acquired Principia Biopharma for $3.7B for BTK inhibitor.
Sanofi received an FDA Complete Response Letter for tolebrutinib in non-relapsing secondary progressive multiple sclerosis (nrSPMS) on December 24, 2025; the…
Sanofi completed the $3.68 billion acquisition of Principia Biopharma, gaining full control of tolebrutinib and additional BTK inhibitors to strengthen its…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Sanofi acquired Principia Biopharma in an all-cash tender offer at $100/share (~$3.68 billion), announced August 17, 2020 and completed September 28, 2020, to build out its autoimmune and neurology pipeline around Principia's oral BTK-inhibitor platform. The two lead assets diverged post-close: rilzabrutinib, a reversible covalent BTK inhibitor, won FDA approval as WAYRILZ on August 29, 2025 for persistent or chronic immune thrombocytopenia (ITP) -- the first BTK inhibitor approved for ITP, with subsequent EU and UAE approvals. Tolebrutinib, the brain-penetrant BTK inhibitor positioned as the deal's headline multiple sclerosis asset, received an FDA Complete Response Letter on December 24, 2025 for non-relapsing secondary progressive MS (nrSPMS); Sanofi stated it would work with the FDA on a path forward.
60K US cases/yr · $3.8B Global ITP Market (2024)
Sanofi acquired Principia for rilzabrutinib (Wayrilz), now first FDA-approved BTK inhibitor for ITP, validating the $3.7B thesis.
Sanofi (Wayrilz) BTK leader in autoimmune. Competes with Amgen (Nplate), Dova (Doptelet), Rigel (Tavalisse) in ITP.
Sanofi completed $3.7B acquisition of Principia Biopharma, gaining rilzabrutinib, a reversible BTK inhibitor for autoimmune diseases.
Rilzabrutinib progressed through Phase 3 in immune thrombocytopenia and autoimmune conditions, positioning as potential best-in-class oral BTK inhibitor.
FDA approved WAYRILZ (rilzabrutinib) for persistent or chronic immune thrombocytopenia -- the first BTK inhibitor approved for ITP, validating the Principia BTK platform Sanofi acquired in 2020.
FDA issued a Complete Response Letter for tolebrutinib in non-relapsing secondary progressive MS, the deal's headline neurology asset; Sanofi to work with FDA on a path forward.
Rilzabrutinib in late-stage trials with FDA filing anticipated. $3.7B bet on differentiated BTK inhibitor has strategic merit but commercial validation pending.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Principia Biopharma (this deal) | 2020 | $3.7B | 41 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2020 deals · Sanofi SA deals · Immunology deals